Loading...
Constellation Pharmaceuticals, Inc.
CNST•NASDAQ
Healthcare
Biotechnology
$33.99
$0.00(0.00%)

Over the past four quarters, Constellation Pharmaceuticals, Inc. demonstrated steady revenue growth, increasing from $0.00 in Q2 2020 to $0.00 in Q1 2021. Operating income reached -$40.23M in Q1 2021, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$39.87M, reflecting operational efficiency. Net income dropped to -$40.07M, with EPS at -$0.84. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan